MedTrace Logo

Non-ablative Er:YAG for Recurrent Candidiasis

NCT06572488 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2024-08-27

No results posted yet for this study

Summary

The objective of the study wa to assess the safety, acceptability and effectiveness of non-ablative Er:YAG laser therapy for treatment of symptoms and microbiological conditions of women with recurrent vulvovaginal candidiasis (RVVC). Eligible patients have received 4 laser therapies within four moths and will be assessed at baseline, 3 months and 9 months after last laser therapy.

The effects of laser therapy have been assessed by following the vaginal microbial status, by assessing the five bothersome symptoms related to vaginal infection (burning, itching, dyspareunia, dysuria, and abnormal discharge), by assessing the overall patient satisfaction, and throughout the study the safety of the laser therapy has been monitored.

Conditions

  • Candidiasis, Vulvovaginal
  • Candidiasis of Vagina
  • Candidiasis, Genital
  • Recurrent Candidiasis of Vagina
  • Infection, Candida
  • Vaginal Yeast Infections

Interventions

DEVICE

Non-ablative SMOOTH mode Er:YAG laser

Four intravaginal treatments within four months.

Sponsors & Collaborators

  • Espacio Gaspar Clinic

    lead OTHER

Principal Investigators

  • Adrian Gaspar, MD · Espacio Gaspar Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2022-09-26
Completion
2022-09-26

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06572488 on ClinicalTrials.gov